ZyVersa Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZVSA research report →
Companywww.zyversa.com
ZyVersa Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases.
- CEO
- Stephen C. Glover
- IPO
- 2022
- Employees
- 7
- HQ
- Weston, FL, US
Price Chart
Valuation
- Market Cap
- $1.46M
- P/E
- -0.80
- P/S
- 0.00
- P/B
- -0.10
- EV/EBITDA
- -36.93
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 27.40%
- ROIC
- -16.53%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-24,952,378,000 · -165.07%
- EPS
- $-4.18 · 50.71%
- Op Income
- $-6,844,787
- FCF YoY
- -67553.25%
Performance & Tape
- 52W High
- $1.67
- 52W Low
- $0.11
- 50D MA
- $0.21
- 200D MA
- $0.18
- Beta
- 0.79
- Avg Volume
- 16.00K
Get TickerSpark's AI analysis on ZVSA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 11, 25 | Cashmere Karen A. | other | 48,100 |
| Jul 11, 25 | Freitag Gregory Gene | other | 11,066 |
| Jul 11, 25 | Glover Stephen C. | other | 136,900 |
| Jul 11, 25 | Finizio Robert G | other | 11,066 |
| Jul 11, 25 | Wolfe Peter | other | 60,100 |
| Jul 11, 25 | Guzman Pablo A. | other | 48,900 |
| Jul 11, 25 | Park Min-Chul | other | 11,066 |
| Jul 11, 25 | SAPIRSTEIN JAMES | other | 11,066 |
| May 24, 23 | Cashmere Karen A. | other | 572 |
| May 24, 23 | Wolfe Peter | other | 715 |
Our ZVSA Coverage
We haven't published any research on ZVSA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ZVSA Report →